Optikerförbundet, September 2026, In Swedish
Meet us at Optometridagarna
We are in Gothenburg on 19 and 20 September. Come by and see how it works, inside the routine eye exam.

During every eye exam, Eyedentity analyses the existing fundus image for signs of disease and delivers decision support within seconds. Same camera, same visit, no extra examination.
The problem
The solution
The image is already there.
Now it gets an instant expert opinion.
The image from the routine exam gets an instant expert opinion.
Image quality is confirmed before anything is read. A poor photo is flagged for a retake instead of being assessed.
The moment the photo is taken, machine learning analyses it. Nothing to click, and no image is ever stored.
A risk assessment and a recommendation, in seconds, while the patient is still in the chair.
Eyedentity runs inside the exam your practices already do.
Clinical foundation
Our melanoma models are trained on longitudinal clinical data in partnership with St. Erik Eye Hospital, where a handful of specialists treat thousands of patients on a national level. On the clinical side it is led by Prof. Gustav Stålhammar, ranked number four in the world in uveal melanoma research.

Our mission


The board
Eyedentity is built by a team and guided by a board that has brought medical technology to market before.

Fredrik Löfman
Chairman of the board
Director of Machine Learning, RaySearch Laboratories

Mats Holmström
CEO and founder
Machine learning, formerly RaySearch Laboratories

Gustav Stålhammar
CSO and founder
Professor, Karolinska Institutet; St. Erik Eye Hospital

Stephanie Tigerschiöld
Board member
Consultant in anaesthesiology and MedTech investor

Anna Fredrixon
Board member
Co-founder and Partner at Norrsken Launcher
Optikerförbundet, September 2026, In Swedish
We are in Gothenburg on 19 and 20 September. Come by and see how it works, inside the routine eye exam.
Karolinska Institutet Innovation, August 2026
Karolinska Institutet Innovation on its incubator company's first round, with Norrsken Launcher as lead investor and the capital going toward regulatory approval and the next steps of the product.
Breakit, August 2026, In Swedish
Breakit on why Norrsken backs Eyedentity in its AI for good category, and on a cancer where survival has not improved in fifty years.
Cancers, 2026
Translational Vision Science & Technology, 2025
Ophthalmology Science, 2025